Patent intelligence · US
US 11596694
Compositions and methods for predicting response to NaPi2b-targeted therapy
Compositions and methods for predicting response to NaPi2b-targeted therapy
Patent details — US 11596694
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 7, 2023
- Expiration
- Mar 2, 2043
- Applicant
- Mersana Therapeutics, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K47/68031, A61K47/6849
Quick answer
US 11596694 (Compositions and methods for predicting response to NaPi2b-targeted therapy) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Mar 7, 2023. Expires Mar 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mersana Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K47/68031, A61K47/6849, A61K47/6857, A61K47/6869
More from Mersana Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 11596694?
US 11596694 (Compositions and methods for predicting response to NaPi2b-targeted therapy) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Mar 7, 2023. Expires Mar 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11596694?
Mersana Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 11596694 expire?
Our index shows an expiration date of Mar 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.